ASCO 2024 | Development of SX-682 and targeting CXCR1 and CXCR2 in melanoma
Sapna Patel, BA, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the rationale behind the development of SX-6, an inhibitor of CXCR1 and CXCR2 (CXCR1/2). CXCR1/2 are chemokine receptors linked to melanoma growth and overexpression of CXCR1/2 are linked to inferior survival outcomes. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Emory University
Consulting or Advisory Role – Bristol Myers Squibb; Cardinal Health; Castle Biosciences; Delcath Systems; IDEAYA Biosciences; immatics; Immunocore; MSD; Novartis; OncoSec; Pfizer; Replimune; TriSalus Life Sciences
Speakers’ Bureau – BMS GmbH & Co. KG; MSD
Research Funding – Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); IDEAYA Biosciences (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses – BMS GmbH & Co. KG; Castle Biosciences; InxMed; TriSalus Life Sciences
